<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2020-01-02">
  <drugbank-id primary="true">DB11063</drugbank-id>
  <name>Polysorbate 80</name>
  <description>Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a&#13;
nonionic surfactant) with ethylene oxide), is used in many foreign countries, including the U.S. and the EU, where it acts as an emulsifier, a solubilizer in many foods, including bread, cake mix, salad dressing, shortening oil and chocolate [L1856].&#13;
&#13;
Polysorbate 80 is a hydrophilic nonionic surfactant. It is utilized as a surfactant in soaps and cosmetics and also as a lubricant in eye drops. In food or pharmaceutical products, it can act as an emulsifier. Polysorbate 80 is an excipient that is used to stabilize aqueous formulations of medications for parenteral administration or vaccinations [L1852].&#13;
&#13;
A solubilizing agent acts as a surfactant and increases the solubility of one agent in another. A substance that would not normally dissolve in a particular solution is able to dissolve with the use of a solubilizing agent [L1852].&#13;
&#13;
&#13;
It is also known as an emulsifier, which helps ingredients mix together and prevent separation, and water-containing small amounts of salts, and is included in several vaccines licensed in the USA [L1844].</description>
  <cas-number>9005-65-6</cas-number>
  <unii>6OZP39ZG8H</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32225</ref-id>
        <pubmed-id>16400901</pubmed-id>
        <citation>Coors EA, Seybold H, Merk HF, Mahler V: Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005 Dec;95(6):593-9. doi: 10.1016/S1081-1206(10)61024-1.</citation>
      </article>
      <article>
        <ref-id>A32226</ref-id>
        <pubmed-id>14967540</pubmed-id>
        <citation>Sun W, Xie C, Wang H, Hu Y: Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials. 2004 Jul;25(15):3065-71. doi: 10.1016/j.biomaterials.2003.09.087.</citation>
      </article>
      <article>
        <ref-id>A32228</ref-id>
        <pubmed-id>21348312</pubmed-id>
        <citation>Zhao YM, Xia AX, Wei YH, Ruan YP, Li FZ: [Polysorbate-80 modified neurotoxin nanoparticle with its transport and cytotoxicity against blood-brain barrier]. Yao Xue Xue Bao. 2010 Oct;45(10):1312-6.</citation>
      </article>
      <article>
        <ref-id>A32229</ref-id>
        <pubmed-id>10537361</pubmed-id>
        <citation>van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A: Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res. 1999 Oct;5(10):2918-24.</citation>
      </article>
      <article>
        <ref-id>A32231</ref-id>
        <pubmed-id>14560928</pubmed-id>
        <citation>Zhang H, Yao M, Morrison RA, Chong S: Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res. 2003 Sep;26(9):768-72.</citation>
      </article>
      <article>
        <ref-id>A32234</ref-id>
        <pubmed-id>19401168</pubmed-id>
        <citation>Wang CX, Huang LS, Hou LB, Jiang L, Yan ZT, Wang YL, Chen ZL: Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res. 2009 Mar 19;1261:91-9. doi: 10.1016/j.brainres.2009.01.011. Epub 2009  Jan 20.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1842</ref-id>
        <title>Polysorbate 80</title>
        <url>https://pubchem.ncbi.nlm.nih.gov/compound/5281955</url>
      </link>
      <link>
        <ref-id>L1843</ref-id>
        <title>Code of Federal Regulation</title>
        <url>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=172.840</url>
      </link>
      <link>
        <ref-id>L1844</ref-id>
        <title>Common Ingredients in U.S. Licensed Vaccines</title>
        <url>https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm187810.htm</url>
      </link>
      <link>
        <ref-id>L1845</ref-id>
        <title>NTP Toxicology and Carcinogenesis Studies of Polysorbate 80 (CAS No. 9005-65-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).</title>
        <url>https://www.ncbi.nlm.nih.gov/pubmed/12616296</url>
      </link>
      <link>
        <ref-id>L1846</ref-id>
        <title>Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study</title>
        <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537525/</url>
      </link>
      <link>
        <ref-id>L1847</ref-id>
        <title>Food Emulsifier Polysorbate 80 Increases Intestinal Absorption of Di-(2-Ethylhexyl) Phthalate in Rats</title>
        <url>https://academic.oup.com/toxsci/article/139/2/317/2511598</url>
      </link>
      <link>
        <ref-id>L1848</ref-id>
        <title>Polysorbates, peroxides, protein aggregation, and immuno- genicity â€“ a growing concern.</title>
        <url>https://pdfs.semanticscholar.org/8b1b/e7f127f8a7ae1c71e62550f4e5a15639c91f.pdf</url>
      </link>
      <link>
        <ref-id>L1851</ref-id>
        <title>In uence of excipients on drug absorption via modulation of intestinal transporters activity</title>
        <url>https://www.asiapharmaceutics.info/index.php/ajp/article/viewFile/435/394</url>
      </link>
      <link>
        <ref-id>L1852</ref-id>
        <title>Polysorbate 80</title>
        <url>https://www.drugs.com/inactive/polysorbate-80-372.html</url>
      </link>
      <link>
        <ref-id>L1853</ref-id>
        <title>Overview of pharmaceutical excipients used in tablets and capsules</title>
        <url>http://biologicpharma.com/wp-content/uploads/Overview-of-pharmaceutical-excipients-used-in-tablets-and-capsules.pdf</url>
      </link>
      <link>
        <ref-id>L1855</ref-id>
        <title>Effect of Polysorbate 80 Quality on Photostability of a Monoclonal Antibody</title>
        <url>https://www.ncbi.nlm.nih.gov/pubmed/22362139</url>
      </link>
      <link>
        <ref-id>L1856</ref-id>
        <title>Evaluation reports of Polysorbates</title>
        <url>http://www.fsc.go.jp/english/evaluationreports/foodadditive/polysorbate_report.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>It is used as a solubilizer, antimicrobial preservative and disinfectant [L1853].</indication>
  <pharmacodynamics>Polysorbates are widely used to protect biological drug products from protein unfolding, aggregation, and precipitation during both shipping and handling. The polysorbates are amphipathic, nonionic surfactants made of fatty acid esters of polyoxyethylene sorbitan. Polysorbate 80 is one of the most common surfactants currently used in the formulation of protein-based biopharmaceuticals [A32234].&#13;
</pharmacodynamics>
  <mechanism-of-action>Polysorbate 80 is one of the primary components of protein formulations. This drug inhibits interfacial damage of the protein molecule that undergoes mechanical stress during shipping and handling. Polysorbate 80 also affects the formulation photostability. Exposure to light of polysorbate 80 aqueous solution results in peroxide generation, which in turn may lead to oxidation of the susceptible amino acid residues in the protein molecule [A32234].&#13;
&#13;
&#13;
One study on rats found that Polysorbate 80 increased apical to basolateral membrane permeability of digoxin in Caco-2 cells suggesting that Ps 80 is an in vitro inhibitor of P-glycoprotein. It concluded that PS 80 may influence in vivo absorption of P-gp substrates, and this could be translated to human applications [A32231].&#13;
&#13;
</mechanism-of-action>
  <toxicity>Acute oral toxicity (LD50): 25000 mg/kg in Mouse [MSDS]&#13;
&#13;
In general, study results of the polysorbates demonstrated no carcinogenicity and genotoxicity. In repeated-dose toxicity studies, diarrhea was observed as the major symptom of toxicity [L1856]. Some studies, however, show conflicting findings.&#13;
&#13;
In a 2-year dietary study of polysorbate 80 in rats, a higher incidence of adrenal medullary pheochromocytomas was found, mainly in male rats [L1856].&#13;
&#13;
Polysorbate 80 is used as a solubilizing agent in IV infusions of the antiarrhythmic drug amiodarone. Rare case reports of liver toxicity have been published suggesting polysorbate 80 may contribute to liver toxicity with the IV formulation of amiodarone. The package labeling of amiodarone warns that polysorbate 80 is also known to leach DEHP (dioctyl phthalate) from PVC and dosing recommendations must be followed closely [L1852].&#13;
&#13;
It was found that maternal toxicities such as loose stool, suppression of weight gain and reduced intake were seen, and poor lactation was noted in some studies of mother rats administered 7.5% solutions of polysorbates [L1856].</toxicity>
  <metabolism>Polysorbates undergo degradation by auto-oxidation, producing reactive peroxides, in addition to hydrolysis [L1848].&#13;
Exposure to light of polysorbate 80 aqueous solution leads autoxidation of the alkyl polyoxyethylene chain leading to the production of hydroperoxide derivatives. The peroxides cause oxidative damage to the protein molecule that makes up the formulation. The residual peroxides and the rate of peroxide generation as a result of light exposure are found to vary for polysorbate 80 of different grades/from different sources [A32234].</metabolism>
  <absorption>Poorly absorbed [L1856].</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">polyoxyethylene-sorbitan-20 mono-oleate</synonym>
    <synonym language="english" coder="inn/usan">Polysorbate 80</synonym>
    <synonym language="english" coder="">Tween 80</synonym>
  </synonyms>
  <products>
    <product>
      <name>Avitears</name>
      <labeller>Pinnacle Science, LLc</labeller>
      <ndc-id/>
      <ndc-product-code>49869-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Eyes Complete 7 Symptom Relief</name>
      <labeller>Prestige Brands Holdings, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67172-595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Eyes Complete 7 Sympton Relief</name>
      <labeller>Prestige Brands Holdings, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67172-707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Endura</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-9235</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>IV Solution Stabilizer</name>
      <labeller>AstraZeneca Pharmaceuticals LP</labeller>
      <ndc-id/>
      <ndc-product-code>0310-4715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>6.5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA761104</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Otovel</name>
      <labeller>Arbor Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>24338-080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>For solution</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA208251</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polysorbate</name>
      <labeller>Eberth Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02026538</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic; Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>REFRESH OPTIVE Advanced</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-4491</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>REFRESH OPTIVE Advanced</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-4307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>REFRESH OPTIVE Advanced</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02399148</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Refresh Optive Advanced Sensitive</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02425815</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>REFRESH OPTIVE Mega-3</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0023-5773</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rohto Beauty Secret</name>
      <labeller>The Mentholatum Company</labeller>
      <ndc-id/>
      <ndc-product-code>10742-8145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rohto Cool</name>
      <labeller>Rohto-Mentholatum (Vietnam) Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>75977-8142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rohto Cool</name>
      <labeller>Rohto Pharmaceutical Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>66613-8142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rohto Cool</name>
      <labeller>The Mentholatum Company</labeller>
      <ndc-id/>
      <ndc-product-code>10742-8142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rohto Cool Max</name>
      <labeller>Rohto Pharmaceutical Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>66613-8159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rohto Cool Max</name>
      <labeller>The Mentholatum Company</labeller>
      <ndc-id/>
      <ndc-product-code>10742-8159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Viva</name>
      <labeller>Dakota Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>54891-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>100 mg/10mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>part349</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Tween-80</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Clear Eyes Complete 7 Symptom Relief</name>
      <ingredients>Hypromellose + Naphazoline + Polysorbate 80 + Zinc sulfate, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Avitears</name>
      <ingredients>Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Viva</name>
      <ingredients>Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Rohto Cool</name>
      <ingredients>Naphazoline + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Rohto Cool Max</name>
      <ingredients>Naphazoline + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Rohto Cool</name>
      <ingredients>Naphazoline + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Otovel</name>
      <ingredients>Ciprofloxacin + Fluocinolone acetonide + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Clear Eyes Complete 7 Sympton Relief</name>
      <ingredients>Hypromellose + Naphazoline + Polysorbate 80 + Zinc sulfate, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>REFRESH OPTIVE Mega-3</name>
      <ingredients>Carboxymethylcellulose + Glycerin + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Rohto Cool Max</name>
      <ingredients>Naphazoline + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>REFRESH OPTIVE Advanced</name>
      <ingredients>Carboxymethylcellulose + Glycerin + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>REFRESH OPTIVE Advanced</name>
      <ingredients>Carboxymethylcellulose + Glycerin + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>IV Solution Stabilizer</name>
      <ingredients>Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Rohto Beauty Secret</name>
      <ingredients>Naphazoline + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Rohto Cool</name>
      <ingredients>Naphazoline + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Endura</name>
      <ingredients>Glycerin + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>REFRESH OPTIVE Advanced</name>
      <ingredients>Carboxymethylcellulose + Glycerin + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Refresh Optive Advanced Sensitive</name>
      <ingredients>Carboxymethylcellulose + Glycerin + Polysorbate 80</ingredients>
    </mixture>
    <mixture>
      <name>Polysorbate</name>
      <ingredients>Polysorbate 80</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Artificial Tears</category>
      <mesh-id>D065346</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Drug Delivery Systems</category>
      <mesh-id>D016503</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Excipients</category>
      <mesh-id>D005079</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Pharmaceutic Aids</category>
      <mesh-id>D010592</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Vehicles</category>
      <mesh-id>D014677</mesh-id>
    </category>
    <category>
      <category>Polyethylene Glycols</category>
      <mesh-id>D011092</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Surface-Active Agents</category>
      <mesh-id>D013501</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Solution / drops</form>
      <route>Topical</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>6.5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>For solution</form>
      <route>Auricular (otic)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic; Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength>100 mg/10mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>52:13.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11063.pdf?1521841424</msds>
  <patents>
    <patent>
      <number>8932610</number>
      <country>United States</country>
      <approved>2015-01-13</approved>
      <expires>2030-03-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Easily soluble in cold water, hot water</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>-20.556</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>100</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6497</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911102</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Polysorbate_80</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>